NYSE:QGEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. More Details


Snowflake Analysis

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has QIAGEN's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QGEN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.7%

QGEN

-1.0%

US Life Sciences

-1.4%

US Market


1 Year Return

76.5%

QGEN

45.1%

US Life Sciences

17.8%

US Market

Return vs Industry: QGEN exceeded the US Life Sciences industry which returned 46.7% over the past year.

Return vs Market: QGEN exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

QGENIndustryMarket
7 Day-3.7%-1.0%-1.4%
30 Day0.5%9.6%4.7%
90 Day3.9%9.6%8.2%
1 Year76.5%76.5%45.3%45.1%20.5%17.8%
3 Year50.0%50.0%93.5%92.3%42.2%32.7%
5 Year110.3%102.4%202.6%198.6%83.4%62.7%

Price Volatility Vs. Market

How volatile is QIAGEN's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is QIAGEN undervalued compared to its fair value and its price relative to the market?

675.01x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: QGEN ($50.58) is trading above our estimate of fair value ($27.31)

Significantly Below Fair Value: QGEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: QGEN is poor value based on its PE Ratio (675x) compared to the US Life Sciences industry average (44.8x).

PE vs Market: QGEN is poor value based on its PE Ratio (675x) compared to the US market (19x).


Price to Earnings Growth Ratio

PEG Ratio: QGEN is poor value based on its PEG Ratio (48.2x)


Price to Book Ratio

PB vs Industry: QGEN is good value based on its PB Ratio (4.8x) compared to the US Life Sciences industry average (6.9x).


Next Steps

Future Growth

How is QIAGEN forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

14.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QGEN's forecast earnings growth (14% per year) is above the savings rate (2.2%).

Earnings vs Market: QGEN's earnings (14% per year) are forecast to grow slower than the US market (22.2% per year).

High Growth Earnings: QGEN's earnings are forecast to grow, but not significantly.

Revenue vs Market: QGEN's revenue (5.1% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: QGEN's revenue (5.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QGEN's Return on Equity is forecast to be low in 3 years time (11.6%).


Next Steps

Past Performance

How has QIAGEN performed over the past 5 years?

-20.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QGEN has a large one-off loss of $315.3M impacting its June 30 2020 financial results.

Growing Profit Margin: QGEN's current net profit margins (1.1%) are lower than last year (11.2%).


Past Earnings Growth Analysis

Earnings Trend: QGEN's earnings have declined by 20% per year over the past 5 years.

Accelerating Growth: QGEN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: QGEN had negative earnings growth (-90%) over the past year, making it difficult to compare to the Life Sciences industry average (14.9%).


Return on Equity

High ROE: QGEN's Return on Equity (0.7%) is considered low.


Next Steps

Financial Health

How is QIAGEN's financial position?


Financial Position Analysis

Short Term Liabilities: QGEN's short term assets ($1.6B) exceed its short term liabilities ($959.7M).

Long Term Liabilities: QGEN's short term assets ($1.6B) do not cover its long term liabilities ($2.0B).


Debt to Equity History and Analysis

Debt Level: QGEN's debt to equity ratio (68.3%) is considered high.

Reducing Debt: QGEN's debt to equity ratio has increased from 41.3% to 68.3% over the past 5 years.

Debt Coverage: QGEN's debt is well covered by operating cash flow (21.2%).

Interest Coverage: QGEN's interest payments on its debt are well covered by EBIT (6.6x coverage).


Balance Sheet


Next Steps

Dividend

What is QIAGEN current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Thierry Bernard (55 yo)

1

Tenure

US$1,208,000

Compensation

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and had been its Interim Chief Executive Officer since October 2019 until March 2020. He has been a Director at T2 Biosy ...


CEO Compensation Analysis

Compensation vs Market: Thierry's total compensation ($USD1.21M) is below average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Insufficient data to compare Thierry's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Thierry Bernard
Chief Executive Officer1yrUS$1.21m0.022%
$ 2.5m
Roland Sackers
CFO, MD & Member of Management Board16.75yrsUS$925.00k0.074%
$ 8.6m
Peer Schatz
Senior Advisor1yrUS$7.55mno data
Barthold Piening
Senior VP & Head of Global Operations1.83yrsno datano data
John Gilardi
Vice President of Corporate Communications & Investor Relations10yrsno datano data
Jean-Pascal Viola
Head of Corporate Business Development5.42yrsno datano data
Stephany Foster
SVP & Head of Human Resources1yrno datano data
Thomas Schweins
Senior Vice President of Life Science Business Area2.75yrsno datano data
Jonathan Sheldon
Senior Vice President of Qiagen Digital Insights Business Area2.75yrsno datano data
Thomas Neidert
Vice President of Global Treasuryno datano datano data
Phoebe Loh
Associate Director of Investor Relationsno datano datano data
Ulrich Schriek
Senior Advisor to the Chief Executive Officer5.42yrsno datano data

2.8yrs

Average Tenure

55yo

Average Age

Experienced Management: QGEN's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Metin Colpan
Independent Supervisory Director16.75yrsUS$75.50k1.55%
$ 179.9m
Elizabeth Tallett
Independent Supervisory Director9.33yrsUS$96.50k0.013%
$ 1.4m
Lawrence Rosen
Independent Chairman of Supervisory Board0.17yrUS$82.50kno data
Elaine Mardis
Independent Supervisory Director6.33yrsUS$63.50k0%
$ 0
Stéphane Bancel
Independent Supervisory Director7.33yrsUS$89.50k0.0070%
$ 805.3k
Ross Levine
Independent Supervisory Director4.75yrsUS$63.50k0.00094%
$ 108.8k

6.8yrs

Average Tenure

60yo

Average Age

Experienced Board: QGEN's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

QIAGEN N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: QIAGEN N.V.
  • Ticker: QGEN
  • Exchange: NYSE
  • Founded: 1986
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$11.570b
  • Shares outstanding: 228.74m
  • Website: https://www.qiagen.com

Number of Employees


Location

  • QIAGEN N.V.
  • Hulsterweg 82
  • Venlo
  • Limburg
  • 5912 PL
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QGENNYSE (New York Stock Exchange)YesCommon SharesUSUSDJun 1996
QIADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 1996
QIAXTRA (XETRA Trading Platform)YesCommon SharesDEEURJun 1996
0RLTLSE (London Stock Exchange)YesCommon SharesGBEURJun 1996
QIADBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJun 1996
QGENSWX (SIX Swiss Exchange)YesCommon SharesCHCHFJun 1996
QGENWBAG (Wiener Boerse AG)YesCommon SharesATEURJun 1996
QIAETLX (Eurotlx)YesCommon SharesITEURJun 1996

Biography

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilizati ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 00:26
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.